DNA

Ginkgo Bioworks Holdings, Inc. Class A Common Stock (DNA) | Rumor.io

Ginkgo Bioworks Holdings

DNA

Attention (50-day avg)0%

Attention rank (50-day avg)#1,122

Bullish sentiment (50-day avg)56%

Price to earnings ratio-1.85

Market capitalization704.4M

Earnings per share-5.33

Dividend yield (TTM)—

Revenue (annual)170.2M

Net income (annual)-312.8M

Social

What share of all stock conversation is about DNA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.02% new	0.01% +0.01	0% +0	0% -0.01

May 7

Ginkgo Bioworks Holdings, Inc. ($DNA) reported Q1 2026 earnings with revenue of $19.47M, down 59.70% YoY, and reaffirmed its full-year 2026 outlook with expected cash burn between -$150M and -$125M.
The company has pivoted to its "Autonomous Labs" business, with initial lab partners including Ginkgo itself and Twist Bioscience ($TWST), and has divested its Biosecurity unit.
Ginkgo has partnered with Amazon ($AMZN) on the Amazon Bio Discovery initiative, which connects AI bio foundation models with a physical lab network to accelerate antibody design.

Generated by AI

Sentiment

Of the messages about DNA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	6.67%	48.97% +4.21	47.18% -46.06	57.55% -29.52
Bearish	93.33%	51.03% -4.21	52.82% +46.06	42.45% +29.52

Bullish· Dec 23

Large institutional funds are quietly accumulating in Ginkgo Bioworks Holdings, Inc. (DNA), which could lead to a rerating of the stock.
The company's 28-year PPAs and +232% YoY growth in Q3 demonstrate predictability and accelerating revenue, reducing guesswork and increasing the stock's potential.
Ginkgo Bioworks Holdings, Inc. (DNA) has a rare combination of triple-digit growth and long contracts, which can amplify upside once attention hits, making it a promising re-rating setup.

Bearish· Mar 22

Ginkgo Bioworks' shift from automated test racks to high-cost lab equipment may be a strategic misstep.
The company's funding for research programs has been stopped, adding to its distress.
Jason Kelly's leadership has been questioned, with some comparing it unfavorably to Elon Musk's success at Tesla.

Generated by AI

Topics

Of the messages about DNA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	72.28%	78.87%	66.32%
Earnings	0%	0%	0%	1.73%
Technical Analysis	100%	27.72%	21.13%	18.64%
Macro	0%	0%	0%	0.74%
Analysts	0%	0%	0%	12.46%
Controversies	0%	0%	0%	0.1%

Earnings· Feb 29

Ginkgo Bioworks Holdings (DNA) reported Q4 2023 earnings, missing estimates with a loss of $0.11 per share and sales of $34.76M, which fell short of the $42.50M estimate.
The company's total revenue decreased by 47% to $251 million in 2023, while biosecurity revenue fell by 68% year-over-year to $108 million.
Ginkgo Bioworks expects to add 100-120 new Cell Programs to its platform in 2024, with total revenue guidance of $215-235 million, representing a decrease from 2023.

Announcements· May 6

Ginkgo Bioworks Holdings, Inc. (DNA) has acquired Patch Biosciences.
DNA will co-sponsor a panel at the SCSPAIExpo2024 on AI's impact on biosecurity.
Ginkgo Bioworks will present at the ASGCT Annual Meeting, highlighting advancements in gene and cell therapy.

Controversies· Oct 6

Ginkgo Bioworks Holdings, Inc. is under investigation for potential securities law violations and securities fraud by several law firms, including Block & Leviton, The Schall Law Firm, Ademi LLP, Hagens Berman, and the Law Offices of Frank R. Cruz.
The investigations are related to allegations of securities law violations and potential false statements made by the company, particularly regarding COVID-19 testing.
Several law firms are encouraging investors who have lost money in their investment in Ginkgo Bioworks Holdings, Inc. to contact them for more information about how to recoup their losses.

Technical Analysis· Oct 6

*DNA is expected to bounce after a strong reversal off the lows, with potential targets at 9.22 and 8.15 based on daily chart technical levels.
A rising wedge pattern has been identified on the 2-minute chart, contradicting bearish pennant calls from other traders.
A bear flag formation is being watched, with a potential breakdown or bounce expected, and a break above $10 could lead to a major squeeze.

Generated by AI

Community

Of the messages about DNA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	95.31%	57.73%	57.4%	47.24%
Newcomers	4.69%	42.27%	42.6%	52.76%

Regulars· Aug 7

Ginkgo Bioworks Holdings reported a net loss of $66M, a 71% decrease from the same quarter last year, despite a 12% decrease in total revenue.
The company's EPS was -$1.1, beating expectations of -$1.44, and its revenue of $49.6M beat market expectations of $41.6M.
The company's automation technology, largely acquired from Zymergen, is being explored as a new growth vector, and its biosecurity guidance was cut by $10M, but its total revenue guidance remains unchanged.

Newcomers· Apr 16

New investors are excited about the strategic catalyst that led to a 3.21% surge in DNA, with many highlighting the launch of Ginkgo Cloud Lab as a key development.
Some newcomers are comparing DNA to other biotech stocks, suggesting that its high-risk, high-reward profile makes it an attractive opportunity for aggressive investors.
There is growing interest in DNA's automation shift, with many users discussing the potential impact of Ginkgo Cloud Lab on the company's business and valuation.

Generated by AI

News

Ginkgo Bioworks: Another Curious Rally (NYSE:DNA)

Ginkgo Bioworks surged on partnership news, but Q2 revenue fell and losses widened as valuation jumps. Click here to read this DNA stock update.

14h agoSeeking Alpha

Ginkgo Bioworks Holdings, Inc. (DNA) Sees a More Significant Dip Than Broader Market: Some Facts to Know

6d agoYahoo Finance

Ginkgo Bioworks (DNA) Surges 11.1%: Is This an Indication of Further Gains?

Ginkgo Bioworks (DNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

11d agoYahoo Finance

Ginkgo Bioworks Holdings, Inc. (DNA) Rises As Market Takes a Dip: Key Facts

Ginkgo Bioworks Holdings, Inc. (DNA) concluded the recent trading session at $7.06, signifying a +1% move from its prior day's close.

13d agoYahoo Finance

Twist Bio, Gingko rise on Lilly TuneLab deals (TWST:NASDAQ)

Twist Bioscience (TWST) stock and Ginkgo Bioworks (DNA) stock gain as companies ink agreements with Eli Lilly’s (LLY) TuneLab R&D platform. Read more here.

13d agoSeeking Alpha

Ginkgo Datapoints Announces Partnership with TuneLab to Close the Gap between AI Models and Lab Data

BOSTON, September 16, 2026--Ginkgo Bioworks (NYSE: DNA) today announced that its Ginkgo Datapoints offering has entered into a new agreement with Lilly TuneLab, a collaborative AI/ML drug discovery platform created by Eli Lilly and Company (Lilly). TuneLab supports biotech innovation by enabling participating companies to access AI/ML drug discovery models trained on decades of Lilly's proprietary research data.

13d agofinance.yahoo.com

Also Discussed

Investors talking about DNA also mention

#	Name	Attention
1	Twist Bioscience CorporationTWST	0%-0.02
2	SYBX - Synlogic, Inc.	——
3	Caribou Biosciences, Inc.CRBU	0%new
4	Beam Therapeutics IncBEAM	0.02%+0.02
5	ARK Genomic Revolution ETFARKG	0.25%+0.09
6	10x Genomics Inc. Class A Common StockTXG	0%-0.02
7	Recursion Pharmaceuticals, Inc. Class A Common StockRXRX	0.01%+0
8	Pacific Biosciences of California, Inc. Common StockPACB	0%0
9	VERV - Verve Therapeutics, Inc.	——
10	Quantum-Si Incorporated Class A Common StockQSI	0.02%+0.02

Ginkgo Bioworks Holdings, Inc. Class A Common Stock

Healthcare
Biotechnology

Ginkgo Bioworks Holdings, Inc. Class A Common Stock represents ownership in Ginkgo Bioworks Holdings, a biotechnology company focused on cell engineering and biological design. Ginkgo Bioworks develops a platform that helps customers design, build, and test custom microbes and other biological systems for use in industries such as pharmaceuticals, agriculture, food, industrial chemicals, and specialty materials. The company provides biological R&D services, automation-enabled laboratory tools, and data-driven software that support the research, development, and commercialization of engineered organisms. It also serves government and commercial clients through biosecurity-related offerings that support biological monitoring and surveillance. Headquartered in Boston, Massachusetts, Ginkgo Bioworks plays a specialized role in the life sciences market by supplying infrastructure and services that make biological engineering more accessible across multiple sectors.

Website

Location

27 Drydock Avenue

Boston, MA, 02210

United States

Social

What share of all stock conversation is about DNA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.02% new	0.01% +0.01	0% +0	0% -0.01

May 7

Ginkgo Bioworks Holdings, Inc. ($DNA) reported Q1 2026 earnings with revenue of $19.47M, down 59.70% YoY, and reaffirmed its full-year 2026 outlook with expected cash burn between -$150M and -$125M.
The company has pivoted to its "Autonomous Labs" business, with initial lab partners including Ginkgo itself and Twist Bioscience ($TWST), and has divested its Biosecurity unit.
Ginkgo has partnered with Amazon ($AMZN) on the Amazon Bio Discovery initiative, which connects AI bio foundation models with a physical lab network to accelerate antibody design.

Generated by AI

Sentiment

Of the messages about DNA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	6.67%	48.97% +4.21	47.18% -46.06	57.55% -29.52
Bearish	93.33%	51.03% -4.21	52.82% +46.06	42.45% +29.52

Bullish· Dec 23

Large institutional funds are quietly accumulating in Ginkgo Bioworks Holdings, Inc. (DNA), which could lead to a rerating of the stock.
The company's 28-year PPAs and +232% YoY growth in Q3 demonstrate predictability and accelerating revenue, reducing guesswork and increasing the stock's potential.
Ginkgo Bioworks Holdings, Inc. (DNA) has a rare combination of triple-digit growth and long contracts, which can amplify upside once attention hits, making it a promising re-rating setup.

Bearish· Mar 22

Ginkgo Bioworks' shift from automated test racks to high-cost lab equipment may be a strategic misstep.
The company's funding for research programs has been stopped, adding to its distress.
Jason Kelly's leadership has been questioned, with some comparing it unfavorably to Elon Musk's success at Tesla.

Generated by AI

Topics

Of the messages about DNA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	72.28%	78.87%	66.32%
Earnings	0%	0%	0%	1.73%
Technical Analysis	100%	27.72%	21.13%	18.64%
Macro	0%	0%	0%	0.74%
Analysts	0%	0%	0%	12.46%
Controversies	0%	0%	0%	0.1%

Earnings· Feb 29

Ginkgo Bioworks Holdings (DNA) reported Q4 2023 earnings, missing estimates with a loss of $0.11 per share and sales of $34.76M, which fell short of the $42.50M estimate.
The company's total revenue decreased by 47% to $251 million in 2023, while biosecurity revenue fell by 68% year-over-year to $108 million.
Ginkgo Bioworks expects to add 100-120 new Cell Programs to its platform in 2024, with total revenue guidance of $215-235 million, representing a decrease from 2023.

Announcements· May 6

Ginkgo Bioworks Holdings, Inc. (DNA) has acquired Patch Biosciences.
DNA will co-sponsor a panel at the SCSPAIExpo2024 on AI's impact on biosecurity.
Ginkgo Bioworks will present at the ASGCT Annual Meeting, highlighting advancements in gene and cell therapy.

Controversies· Oct 6

Ginkgo Bioworks Holdings, Inc. is under investigation for potential securities law violations and securities fraud by several law firms, including Block & Leviton, The Schall Law Firm, Ademi LLP, Hagens Berman, and the Law Offices of Frank R. Cruz.
The investigations are related to allegations of securities law violations and potential false statements made by the company, particularly regarding COVID-19 testing.
Several law firms are encouraging investors who have lost money in their investment in Ginkgo Bioworks Holdings, Inc. to contact them for more information about how to recoup their losses.

Technical Analysis· Oct 6

*DNA is expected to bounce after a strong reversal off the lows, with potential targets at 9.22 and 8.15 based on daily chart technical levels.
A rising wedge pattern has been identified on the 2-minute chart, contradicting bearish pennant calls from other traders.
A bear flag formation is being watched, with a potential breakdown or bounce expected, and a break above $10 could lead to a major squeeze.

Generated by AI

Community

Of the messages about DNA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	95.31%	57.73%	57.4%	47.24%
Newcomers	4.69%	42.27%	42.6%	52.76%

Regulars· Aug 7

Ginkgo Bioworks Holdings reported a net loss of $66M, a 71% decrease from the same quarter last year, despite a 12% decrease in total revenue.
The company's EPS was -$1.1, beating expectations of -$1.44, and its revenue of $49.6M beat market expectations of $41.6M.
The company's automation technology, largely acquired from Zymergen, is being explored as a new growth vector, and its biosecurity guidance was cut by $10M, but its total revenue guidance remains unchanged.

Newcomers· Apr 16

New investors are excited about the strategic catalyst that led to a 3.21% surge in DNA, with many highlighting the launch of Ginkgo Cloud Lab as a key development.
Some newcomers are comparing DNA to other biotech stocks, suggesting that its high-risk, high-reward profile makes it an attractive opportunity for aggressive investors.
There is growing interest in DNA's automation shift, with many users discussing the potential impact of Ginkgo Cloud Lab on the company's business and valuation.

Generated by AI

Ginkgo Bioworks Holdings

Social

May 7

Bullish· Dec 23

Bearish· Mar 22

Earnings· Feb 29

Announcements· May 6

Controversies· Oct 6

Technical Analysis· Oct 6

Regulars· Aug 7

Newcomers· Apr 16

Ginkgo Bioworks: Another Curious Rally (NYSE:DNA)

Ginkgo Bioworks Holdings, Inc. (DNA) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Ginkgo Bioworks (DNA) Surges 11.1%: Is This an Indication of Further Gains?

Ginkgo Bioworks Holdings, Inc. (DNA) Rises As Market Takes a Dip: Key Facts

Twist Bio, Gingko rise on Lilly TuneLab deals (TWST:NASDAQ)

Ginkgo Datapoints Announces Partnership with TuneLab to Close the Gap between AI Models and Lab Data

Also Discussed

Ginkgo Bioworks Holdings, Inc. Class A Common Stock

Company Information

Location

Ginkgo Bioworks: Another Curious Rally (NYSE:DNA)

Ginkgo Bioworks Holdings, Inc. (DNA) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Ginkgo Bioworks (DNA) Surges 11.1%: Is This an Indication of Further Gains?

Ginkgo Bioworks Holdings, Inc. (DNA) Rises As Market Takes a Dip: Key Facts

Twist Bio, Gingko rise on Lilly TuneLab deals (TWST:NASDAQ)

Ginkgo Datapoints Announces Partnership with TuneLab to Close the Gap between AI Models and Lab Data

Also Discussed

Social

May 7

Bullish· Dec 23

Bearish· Mar 22

Earnings· Feb 29

Announcements· May 6

Controversies· Oct 6

Technical Analysis· Oct 6

Regulars· Aug 7

Newcomers· Apr 16